Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD5492 |
Synonyms | |
Therapy Description |
AZD5492 is a trispecific target-induced T-cell activating nanobody targeting CD20 on tumor cells, TCR, and CD8, which potentially induces activation of T-cells and enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5492 | AZD-5492|AZD 5492 | CD20 Antibody 25 CD3 Antibody 103 | AZD5492 is a trispecific target-induced T-cell activating nanobody targeting CD20 on tumor cells, TCR, and CD8, which potentially induces activation of T-cells and enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06542250 | Phase Ib/II | AZD5492 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS | 2 |